Saturday, 19 May 2012
Tuesday, 17 May 2011
Wednesday, 21 July 2010
Sunday, 31 January 2010
Concerns over the Seroxat Group Litigation
Due to a situation here and around the internet, I have felt unable to progress or use this blog for the purpose it was intended.
As a result I’m taking time out from statistics and associated issues - as yet unpublished - to facilitate publishing information appertaining to the UK Seroxat Litigation which, having been in the public domain since it was preannounced in 2001/2, is going to court this year.
The information encompasses the UK Government Prescription Cost Analysis (PCA) statistics - although at the time of publication of this blog - I was unaware of one significant fact and therefore revelations were unintentional.
However, a few weeks after its publication, on first sight of the Seroxat Group Litigation Order no: 68 it became glaringly obvious that inadvertently, the statistics – not me – undermine the Litigation.
Since becoming aware of and involved with the SSRI drug forums in 2001, I have spoken out - not against the litigation - but in concern for those involved and anyone taking SSRI, SNRI drugs, especially those choosing to or being swapped without consideration from Seroxat to other drugs in the class including Prozac, Lustral and Efexor.
The statistics are, unfortunately, not the only jeopardy to the frail legal case being successful - Seroxat has a certain notoriety for being “the worst drug” in the class - but is that notoriety well-substantiated or solely due to outside influences? Do the experts agree?
Have the UK population been let down by the government, medicines authorities and the media?
The new Seroxat Litigation Blog will hopefully extricate the distinct facts, clarify, assemble and publicise each in context - to let the readers decide for them selves.
The new blog content will possibly adversely impact on the few hundred people who have not been culled from the originally quoted 10.000 prospective litigants ...... but the full ramifications of not speaking out will possibly impact on thousands or even millions.
I have no conflicting interests.
The UK Seroxat Litigation Chronicles - a work in progress - can be found here.
As a result I’m taking time out from statistics and associated issues - as yet unpublished - to facilitate publishing information appertaining to the UK Seroxat Litigation which, having been in the public domain since it was preannounced in 2001/2, is going to court this year.
The information encompasses the UK Government Prescription Cost Analysis (PCA) statistics - although at the time of publication of this blog - I was unaware of one significant fact and therefore revelations were unintentional.
However, a few weeks after its publication, on first sight of the Seroxat Group Litigation Order no: 68 it became glaringly obvious that inadvertently, the statistics – not me – undermine the Litigation.
Since becoming aware of and involved with the SSRI drug forums in 2001, I have spoken out - not against the litigation - but in concern for those involved and anyone taking SSRI, SNRI drugs, especially those choosing to or being swapped without consideration from Seroxat to other drugs in the class including Prozac, Lustral and Efexor.
The statistics are, unfortunately, not the only jeopardy to the frail legal case being successful - Seroxat has a certain notoriety for being “the worst drug” in the class - but is that notoriety well-substantiated or solely due to outside influences? Do the experts agree?
Have the UK population been let down by the government, medicines authorities and the media?
The new Seroxat Litigation Blog will hopefully extricate the distinct facts, clarify, assemble and publicise each in context - to let the readers decide for them selves.
The new blog content will possibly adversely impact on the few hundred people who have not been culled from the originally quoted 10.000 prospective litigants ...... but the full ramifications of not speaking out will possibly impact on thousands or even millions.
I have no conflicting interests.
The UK Seroxat Litigation Chronicles - a work in progress - can be found here.
Thursday, 28 January 2010
Total Prescriptions, Increases & Paroxetine - Seroxat
Paroxetine Seroxat Paxil Aropax Pondera Paroxat Deroxat Cebrilin
Thursday, 7 May 2009
SSRI / SNRI: Statistic Graphs: 1998 to 2008
UK Department of Health, Prescription Cost Analysis (PCA) Statistics for England, 1998 to 2008 transposed to graph form.
Prescriptions & Annual Increases
Click image to enlargehttp://farm4.static.flickr.com/3337/3492596460_045aef0c28_o.jpg
1998 total prescriptions for the SSRI / SNRI drug class were 8,27 Million, in 2008 total prescriptions for just one of the drug class, Citalopram / Cipramil, were over 8.99 Million.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
P–2 Tuesday
Totals, Prescriptions & Increases
Click image to enlargehttp://farm4.static.flickr.com/3591/3492594974_74196089f1_o.jpg
1998 to 2008 the total median increase in SSRI / SNRIs prescriptions was over 1.61 Million.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
P–1 Tuesday
Prescription & Increase Totals
Click image to enlargehttp://farm4.static.flickr.com/3331/3492055975_b1ef73c293_o.jpg
The obvious 2004 to 2005 marginal trends reversal of Total Annual Prescription Increases correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004
http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
2 The "House of Commons, Health Committee’s examination into The Influence of the Pharmaceutical Industry" - initiated June 2004 - report published April 5th 2005
http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
P-3 Tuesday
Prescribing Trend Decreases from 2004
Click image to enlargehttp://farm4.static.flickr.com/3353/3492063913_e42dddd151_o.jpg
The obvious sharp marginal trend reversal of Venlafaxine Total Prescriptions in 2004 to 2006 correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004; which single out Venlafaxine for its potential for cardiotoxicity and toxicity in overdose.
http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
2 “NICE Clinical Guidelines 23: Depression” published December 2004, issued new guidelines for treatment with Venlafaxine; 1.5.2.16 restricting treatment initiation to specialist mental health medical practitioners and in 1.5.2.17 reinforcing that venlafaxine treatment should only be managed under supervision of specialist mental health medical practitioners.
http://www.bpd-mind.fsnet.co.uk/NICE_Depression.pdf
Both 1.5.2.16 and 1.5.2.17 recommendations were surreptitiously deleted from the revised prescribing advice issued 31 May 2006 at which point increasing venlafaxine prescription trends resumed.
http://www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
11-P-04 Tuesday
Prescribing Trends Shift from Paroxetine 2001
Click image to enlargehttp://farm4.static.flickr.com/3640/3492881456_528c138c6a_o.jpg
The marginal trend reversal of Paroxetine Total Prescriptions in 2001 correlates with: -
1 USA – August 2001, Paxil (Paroxetine / Seroxat) GSK class action Lawsuit filed in California Superior Court, LA County, USA.
http://www.onlinelawyersource.com/paxil/class-action.html
2 UK - The Guardian, December 10, 2001 article “Anti-depressant 'addicts' threaten legal Case”, publicises that solicitors Graham Ross of Ross & Co, Wirral, and Mark Harvey of Hugh James Ford Simey, Cardiff (Now Hugh James) who had liaised with American lawyers about Paxil are investigating the possibility of a UK Seroxat class action.
http://www.guardian.co.uk/uk/2001/dec/10/medicalscience.highereducation
The increase in the marginal trend reversal of Paroxetine Total Prescriptions in 2002 correlates with: -
3 UK – The Observer February 3, 2002 article “Hard habit to break”, Mark Harvey, of Hugh James Solicitors, Cardiff; instigates further publicity of the adverse drug reactions (ADRs), side effects and withdrawal problems, connected with the Seroxat --- but common to all drugs in the SSRI / SNRI class.
http://www.guardian.co.uk/Archive/Article/0,4273,4348653,00.html.
4 UK - The Observer, Sunday April 28 2002 “The chemistry of happiness“
http://www.guardian.co.uk/theobserver/2002/apr/28/features.magazine37
5 UK - The November 11th 2002 Parmjit Dhanda Early Day Motion, EDM 238 Seroxat, brought the drug and the SSRI issue to Parliament,
http://edmi.parliament.uk/EDMi/EDMDetails.aspx?EDMID=24050&SESSION=681
The acceleration of the marginal trend reversal of Paroxetine Total Prescriptions in 2003 correlates to: -
6 UK - The ensuing parliamentary questions, media coverage and MIND Seroxat Protest, May 12th 2003 at the MHRA London offices, which made national television news coverage
http://www.mind.org.uk/News+policy+and+campaigns/Press+archive/PRPanoramaSeroxat.htm
The Proxetine prescribing trend continues to decline, all be it at a slower rate.
Significantly, the parliamentary interest and media coverage given to Seroxat and the continuing down trend in Paroxetine prescriptions has had NO impact on the overall marginal trend increases in prescription numbers for the drug class, although ALL are affected by the same ADRs, side effects and withdrawal problems.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
12-P-01p Tuesday
Marginal Trends in Prescribing Change 2004 to 2005
Click image to enlargehttp://farm4.static.flickr.com/3328/3498274531_2612922799_o.jpg
The obvious marginal trend change in Total Prescriptions 2004 to 2006 correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004 – which found the drug class lacking in safety and efficacy, not notably better than placebo.
http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
2 The "House of Commons, Health Committee’s examination into The Influence of the Pharmaceutical Industry" - initiated June 2004 - report published April 5th 2005.
http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf
3 “NICE Clinical Guidelines 23: Depression” published December 2004, issued new guidelines for treatment of depression with the introduction of the “Watchful waiting”; 1.4.1.2 a 2 week waiting period for patients with mild depression who did not want an intervention; and in 1.4.1.3 the GP to contact if the 2 week follow-up appointment not kept; and the restricting treatment initiation and management of Venlafaxine; 1.5.2.16 and in 1.5.2.17 to specialist mental health medical practitioners.
http://www.bpd-mind.fsnet.co.uk/NICE_Depression.pdf
The marginal trend change in Total Prescriptions 2004, caused the anomaly of a Total Prescription Increase of only 402.6 Thousand; the lowest annual SSRI / SNRI drug class increase in prescriptions in the 10 years available statistics.
Adjusting the median increases in SSRI / SNRIs total prescriptions 1998 to 2008 by removing year 2004 from the equation, increases the median total for 9 of the 10 years from over 1.61 Million per annum to over 1.74 Million.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
9–P-04 Tuesday
Total Drug Net Costs
Click image to enlarge
http://farm4.static.flickr.com/3360/3492873728_496fde0913_o.jpg
1998, total net costs of prescriptions for the SSRI / SNRI drug class were £174,59 Million, these cost peaked in 2004 at £355,44 Million and have subsequently reduced by £159,83 Million to £195,6 Million in 2008.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
4-C Tuesday
Net Drug Costs Variation
Click image to enlargehttp://farm4.static.flickr.com/3596/3510317298_68b3f57c16_o.jpg
The obvious 2004 to 2005 marginal trends reversal of Total Annual Net Costs for SSRI / SNRI Prescriptions correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004
http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
2 The "House of Commons, Health Committee’s examination into The Influence of the Pharmaceutical Industry" - initiated June 2004 - report published April 5th 2005
http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
10–C-04 1 Tuesday
Prescription & Net Drug Cost Totals
Click image to enlargehttp://farm4.static.flickr.com/3548/3492877450_5e6fe93c12_o.jpg
In the 10 years of available statistics, the 2008 SSRI / SNRI Total Annual Net Costs of £195.6 Million were the lowest since 1998, when Total Net Costs were £174,59 Million.
In 2008 £159,83 Million less cost, brought 16,1 Million more prescriptions than in 1998, when Total Prescription were 8,27 Million.
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
7-PC Tuesday
Annual Prescriptions, Increases & Net Cost Totals
Click any image to enlargehttp://farm4.static.flickr.com/3327/3510484082_2cd7df45e1_o.jpg
http://farm4.static.flickr.com/3347/3510633522_63041d1702_o.jpg
http://farm4.static.flickr.com/3385/3510660774_3dac575f0a_o.jpg
****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
8-P 2/9-P-04 2/10-C04 2 Tuesday
Subscribe to:
Posts (Atom)